Scolaris Content Display Scolaris Content Display

Esteroides anabolizantes para el tratamiento de las úlceras por presión

Appendices

Appendix 1. Stages of pressure ulcers

The characteristics of pressure ulcers are categorised into 4 stages (EPUAP/NPUAP 2009).

Stage I: non‐blanchable redness of intact skin

Intact skin with non‐blanchable erythema of a localised area usually over a bony prominence. Discoloration of the skin, warmth, oedema, hardness or pain may also be present. Darkly pigmented skin may not have visible blanching.

Stage II: partial thickness skin loss or blister

Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink wound bed, without slough. May also present as an intact or open/ruptured serum‐filled or sero‐sanguinous filled blister.

Stage III: full thickness skin loss (fat visible)

Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or muscle are not exposed. Some slough may be present. May include undermining and tunnelling.

Stage IV: full thickness tissue loss (muscle/bone visible)

Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar may be present. Often include undermining and tunnelling (EPUAP/NPUAP 2009).

Appendix 2. Search strategies

Cochrane Wounds Specialised Register

1 MESH DESCRIPTOR Pressure Ulcer EXPLODE ALL AND INREGISTER
2 (pressure next (ulcer* or sore* or injur*)) AND INREGISTER
3 (decubitus next (ulcer* or sore*)) AND INREGISTER
4 (bedsore* or (bed next sore*)) AND INREGISTER
5 #1 OR #2 OR #3 OR #4
6 MESH DESCRIPTOR Anabolic Agents EXPLODE ALL AND INREGISTER
7 MESH DESCRIPTOR testosterone EXPLODE ALL AND INREGISTER
8 MESH DESCRIPTOR Oxandrolone EXPLODE ALL AND INREGISTER
9 MESH DESCRIPTOR Nandrolone EXPLODE ALL AND INREGISTER
10 MESH DESCRIPTOR Mesterolone EXPLODE ALL AND INREGISTER
11 MESH DESCRIPTOR Oxymetholone EXPLODE ALL AND INREGISTER
12 (anabolic next (steroid* or agent*)) AND INREGISTER
13 testosterone AND INREGISTER
14 oxandrolone AND INREGISTER
15 nandrolone AND INREGISTER
16 mesterolone AND INREGISTER
17 oxymetholone AND INREGISTER
18 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
19 #5 AND #18

The Cochrane Central Register of Controlled Trials (CENTRAL)

#1 MeSH descriptor: [Pressure Ulcer] explode all trees
#2 (pressure next (ulcer* or sore* or injur*)):ti,ab,kw
#3 (decubitus next (ulcer* or sore*)):ti,ab,kw
#4 (bedsore* or (bed next sore*)):ti,ab,kw
#5 {or #1‐#4}
#6 MeSH descriptor: [Anabolic Agents] explode all trees
#7 MeSH descriptor: [Testosterone] explode all trees
#8 MeSH descriptor: [Oxandrolone] explode all trees
#9 MeSH descriptor: [Nandrolone] explode all trees
#10 MeSH descriptor: [Mesterolone] explode all trees
#11 MeSH descriptor: [Oxymetholone] explode all trees
#12 (anabolic next (steroid* or agent*)):ti,ab,kw
#13 testosterone:ti,ab,kw
#14 oxandrolone:ti,ab,kw
#15 nandrolone:ti,ab,kw
#16 mesterolone:ti,ab,kw#17 oxymetholone:ti,ab,kw
#18 {or #6‐#17}
#19 #5 and #18

Ovid MEDLINE

1 exp Pressure Ulcer/
2 (pressure adj (ulcer* or sore* or injur*)).tw.
3 (decubitus adj (ulcer* or sore*)).tw.
4 (bedsore* or (bed adj sore*)).tw.
5 or/1‐4
6 exp Anabolic Agents/
7 exp Testosterone/
8 exp Oxandrolone/
9 exp Nandrolone/
10 exp Mesterolone/
11 exp Oxymetholone/
12 (anabolic adj (steroid* or agent*)).tw.
13 testosterone.tw.
14 oxandrolone.tw.
15 nandrolone.tw.
16 mesterolone.tw.
17 oxymetholone.tw.
18 or/6‐17
19 and/5,18
20 randomised controlled trial.pt.
21 controlled clinical trial.pt.
22 randomi?ed.ab.
23 placebo.ab.
24 clinical trials as topic.sh.
25 randomly.ab.
26 trial.ti.
27 or/20‐26
28 exp animals/ not humans.sh.
29 27 not 28
30 19 and 29

Ovid Embase

1 exp decubitus/
2 (pressure adj (ulcer* or sore* or injur*)).tw.
3 (decubitus adj (ulcer* or sore*)).tw.
4 (bedsore* or (bed adj sore*)).tw.
5 or/1‐4
6 exp anabolic agent/
7 exp testosterone/
8 exp testosterone ester/
9 exp epitestosterone/
10 exp testosterone derivative/
11 exp methenolone/
12 exp methyltestosterone/
13 exp testosterone propionate/
14 exp oxandrolone/
15 exp nandrolone/
16 exp mesterolone/
17 exp oxymetholone/
18 (anabolic adj (steroid* or agent*)).tw.
19 testosterone.tw.
20 oxandrolone.tw.
21 nandrolone.tw.
22 mesterolone.tw.
23 oxymetholone.tw.
24 or/6‐23
25 and/5,24
26 Randomized controlled trials/
27 Single‐Blind Method/
28 Double‐Blind Method/
29 Crossover Procedure/
30 (random$ or factorial$ or crossover$ or cross over$ or cross‐over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab.
31 (doubl$ adj blind$).ti,ab.
32 (singl$ adj blind$).ti,ab.
33 or/26‐32
34 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
35 human/ or human cell/
36 and/34‐35
37 34 not 36
38 33 not 37
39 25 and 38

EBSCO CINAHL Plus

S30 S16 AND S29
S29 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28
S28 TI allocat* random* or AB allocat* random*
S27 MH "Quantitative Studies"
S26 TI placebo* or AB placebo*
S25 MH "Placebos"
S24 TI random* allocat* or AB random* allocat*
S23 MH "Random Assignment"
S22 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S21 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S20 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S19 TI clinic* N1 trial* or AB clinic* N1 trial*
S18 PT Clinical trial
S17 MH "Clinical Trials+"
S16 S6 AND S15
S15 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14
S14 TI oxymetholone OR AB oxymetholone
S13 TI mesterolone OR AB mesterolone
S12 TI nandrolone OR AB nandrolone
S11 TI oxandrolone OR AB oxandrolone
S10 TI testosterone OR AB testosterone
S9 TI "anabolic steroid*" OR AB "anabolic steroid*" OR TI "anabolic agent*" OR AB "anabolic agent*"
S8 (MH "Testosterone+")
S7 (MH "Anabolic Steroids")
S6 S1 OR S2 OR S3 OR S4 OR S5
S5 TI (bed sore*) OR AB (bed sore*)
S4 TI bedsore* OR AB bedsore*
S3 TI decubitus or AB decubitus
S2 TI (pressure ulcer*) OR AB (pressure ulcer*) OR TI (pressure sore*) OR AB (pressure sore*) OR TI (pressure injur*) OR AB (pressure injur*)
S1 (MH "Pressure Ulcer+")

US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov)

"anabolic steroid" AND "pressure ulcer"

"anabolic agent" AND "pressure ulcer"

"testosterone" AND "pressure ulcer"

"oxandrolone" AND "pressure ulcer"

World Health Organization International Clinical Trials Registry Platform

"anabolic steroid" OR "anabolic agent" OR "oxandrolone" AND "pressure ulcer"

Appendix 3. Risk of bias assessment criteria

1. Was the allocation sequence randomly generated?

Low risk of bias:

The investigators describe a random component in the sequence generation process such as: referring to a random number table; using a computer random‐number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.

High risk of bias:

The investigators describe a non‐random component in the sequence generation process. Usually, the description would involve some systematic, non‐random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.

Unclear:

Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.

2. Was the treatment allocation adequately concealed?

Low risk of bias:

Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based and pharmacy‐controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.

High risk of bias:

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: use of an open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. envelopes were unsealed, non‐opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear:

Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.

3. Blinding ‐ was knowledge of the allocated interventions adequately prevented during the study (participants and outcome assessors)?

Low risk of bias:

Any one of the following:

  • No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.

  • Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non‐blinding of others unlikely to introduce bias.

High risk of bias:

Any one of the following:

  • No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.

  • Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.

  • Either participants or some key study personnel were not blinded, and the non‐blinding of others likely to introduce bias.

Unclear:

Either of the following:

  • Insufficient information to permit judgement of low or high risk of bias.

  • The study did not address this outcome.

4. Were incomplete outcome data adequately addressed?

Low risk of bias:

Any one of the following:

  • No missing outcome data.

  • Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias).

  • Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size.

  • Missing data have been imputed using appropriate methods.

High risk of bias:

Any one of the following:

  • Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.

  • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate.

  • For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size.

  • ‘As‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.

  • Potentially inappropriate application of simple imputation.

Unclear:

Either of the following:

  • Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated, no reasons for missing data provided).

  • The study did not address this outcome.

5. Are reports of the study free of suggestion of selective outcome reporting?

Low risk of bias:

Either of the following:

  • The study protocol is available and all of the study’s pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way.

  • The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon).

High risk of bias:

Any one of the following:

  • Not all of the study’s pre‐specified primary outcomes have been reported.

  • One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. sub scales) that were not pre‐specified.

  • One or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect).

  • One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis.

  • The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear:

Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.

6. Other sources of potential bias

Low risk of bias:

The study appears to be free of other sources of bias.

High risk of bias:

There is at least one important risk of bias. For example, the study:

  • had a potential source of bias related to the specific study design used; or

  • has been claimed to have been fraudulent; or

  • had some other problem.

Unclear:

There may be a risk of bias, but there is either:

  • insufficient information to assess whether an important risk of bias exists; or

  • insufficient rationale or evidence that an identified problem will introduce bias.

Study flow diagram
Figuras y tablas -
Figure 1

Study flow diagram

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Comparison 1 Oxandrolone compared with placebo, Outcome 1 Completed healing at 24 week.
Figuras y tablas -
Analysis 1.1

Comparison 1 Oxandrolone compared with placebo, Outcome 1 Completed healing at 24 week.

Comparison 1 Oxandrolone compared with placebo, Outcome 2 Non‐serious adverse events.
Figuras y tablas -
Analysis 1.2

Comparison 1 Oxandrolone compared with placebo, Outcome 2 Non‐serious adverse events.

Comparison 1 Oxandrolone compared with placebo, Outcome 3 Serious adverse events.
Figuras y tablas -
Analysis 1.3

Comparison 1 Oxandrolone compared with placebo, Outcome 3 Serious adverse events.

Summary of findings for the main comparison. Anabolic steroids for treating pressure ulcers

Anabolic steroids for treating pressure ulcers

Patient or population: people with pressure ulcers
Settings: any

Intervention: anabolic steroids

Comparison: placebo or no anabolic steroids

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Certainty of the evidence
(GRADE)

Assumed risk

Corresponding risk

Control

Anabolic steroids

Proportion of wounds completely healed at 24 weeks

298 per 1000

241 per 1000
(155 to 376)

RR 0.81

(0.52 to 1.26)

212
(1 trial)

⊕⊝⊝⊝
very low1,2,3

Non‐serious adverse events

29 per 1000

131 per 1000
(33 to 443)

RR 3.85

(1.12 to 13.26)

212
(1 trial)

⊕⊕⊝⊝

low2,3,4

Serious adverse events

154 per 1000

83 per 1000
(38 to 180)

RR 0.54

(0.25 to 1.17)

212
(1 trial)

⊕⊝⊝⊝
very low1,2,3

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio

GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.
Low quality:our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

1A wide 95% CI, which spanned both benefit and harm.
2Most of the participants in the oxandrolone group (98.2%) and all participants in the placebo group (100%) were men.
3Total sample size (n = 212) was lower than the original target sample size (n = 400): not downgraded as early stopping according to futility stopping criteria will not lead to substantial bias.
4A wide 95% CI.

Figuras y tablas -
Summary of findings for the main comparison. Anabolic steroids for treating pressure ulcers
Table 1. List of reported non‐serious adverse events

Description

Oxandrolone group

n = 108

Placebo group

n = 104

Elevated liver enzyme levels

5

1

Deep venous thrombosis

3

0

Elevated prostate specific antigen

0

1

Severe osteomyelitisa

1

0

Sepsis, secondary cellulitisa

1

0

Medical illnessa

2

1

aIn the trial investigators' judgement these events were not associated with oxandrolone

Figuras y tablas -
Table 1. List of reported non‐serious adverse events
Table 2. List of reported serious adverse events

Description

Oxandrolone group

n = 108

Placebo group

n = 104

Deatha

3

5

Myocutaneous flap surgerya

5

9

Elevated bladder stone removal liver enzyme levelsa

1

0

Small bowel obstruction, renal failurea

0

1

Oral cancera

0

1

aIn the trial investigators' judgement these events were not associated with oxandrolone

Figuras y tablas -
Table 2. List of reported serious adverse events
Comparison 1. Oxandrolone compared with placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Completed healing at 24 week Show forest plot

1

212

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.52, 1.26]

2 Non‐serious adverse events Show forest plot

1

212

Risk Ratio (M‐H, Fixed, 95% CI)

3.85 [1.12, 13.26]

3 Serious adverse events Show forest plot

1

212

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.25, 1.17]

Figuras y tablas -
Comparison 1. Oxandrolone compared with placebo